Koffel Erin, Kats Allyson M, Kroenke Kurt, Bair Matthew J, Gravely Amy, DeRonne Beth, Donaldson Melvin T, Goldsmith Elizabeth S, Noorbaloochi Siamak, Krebs Erin E
Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, Minnesota.
Department of Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota.
Pain Med. 2020 Jun 1;21(6):1162-1167. doi: 10.1093/pm/pnz221.
Sleep disturbance may limit improvement in pain outcomes if not directly addressed in treatment. Moreover, sleep problems may be exacerbated by opioid therapy. This study examined the effects of baseline sleep disturbance on improvement in pain outcomes using data from the Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) trial, a pragmatic 12-month randomized trial of opioid vs nonopioid medication therapy.
Participants with chronic back pain or hip or knee osteoarthritis pain were randomized to either opioid therapy (N = 120) or nonopioid medication therapy (N = 120).
We used mixed models for repeated measures to 1) test whether baseline sleep disturbance scores modified the effect of opioid vs nonopioid treatment on pain outcomes and 2) test baseline sleep disturbance scores as a predictor of less improvement in pain outcomes across both treatment groups.
The tests for interaction of sleep disturbance by treatment group were not significant. Higher sleep disturbance scores at baseline predicted less improvement in Brief Pain Inventory (BPI) interference (β = 0.058, P = 0.0002) and BPI severity (β = 0.026, P = 0.0164).
Baseline sleep disturbance adversely affects pain response to treatment regardless of analgesic regimen. Recognition and treatment of sleep impairments that frequently co-occur with pain may optimize outcomes.
如果在治疗中不直接解决睡眠障碍问题,可能会限制疼痛治疗效果的改善。此外,阿片类药物治疗可能会加剧睡眠问题。本研究利用镇痛药处方比较有效性策略(SPACE)试验的数据,探讨基线睡眠障碍对疼痛治疗效果改善的影响。SPACE试验是一项为期12个月的实用随机试验,比较阿片类药物与非阿片类药物治疗。
患有慢性背痛或髋或膝骨关节炎疼痛的参与者被随机分为阿片类药物治疗组(N = 120)或非阿片类药物治疗组(N = 120)。
我们使用重复测量的混合模型来:1)测试基线睡眠障碍评分是否改变了阿片类药物与非阿片类药物治疗对疼痛治疗效果的影响;2)测试基线睡眠障碍评分是否可预测两个治疗组疼痛治疗效果改善较少的情况。
治疗组睡眠障碍的交互作用测试无显著意义。基线时较高的睡眠障碍评分预示着简明疼痛量表(BPI)干扰项(β = 0.058,P = 0.0002)和BPI严重程度项(β = 0.026,P = 0.0164)的改善较少。
无论镇痛方案如何,基线睡眠障碍都会对治疗的疼痛反应产生不利影响。识别并治疗经常与疼痛同时出现的睡眠障碍可能会优化治疗效果。